Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience.
DNA mismatch repair
Endometrial cancer
Lynch syndrome
MLH1 hypermethylation
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
09
10
2020
accepted:
11
02
2021
pubmed:
13
3
2021
medline:
26
11
2021
entrez:
12
3
2021
Statut:
ppublish
Résumé
Current guidelines for Lynch syndrome detection in endometrial cancer (EC) patients rely either on risk evaluation, based on personal/family history, or detection of mismatch repair (MMR) deficiency on tumor tissue. We present a combined screening algorithm for Lynch syndrome. In this study, 213 consecutive patients treated for EC at Kliniken Essen-Mitte between 2014 and 2018 were included. Personal/family history was evaluated by the Amsterdam II, revised Bethesda/German-DKG criteria and prediction model PREMM Based on personal/family history 2/213 (Amsterdam II), 31/213 (revised Bethesda/German-DKG) and 149/213 (PREMM General MMR assessment is a feasible strategy to improve the detection of Lynch Syndrome in patients with EC.
Identifiants
pubmed: 33710393
doi: 10.1007/s00404-021-06006-w
pii: 10.1007/s00404-021-06006-w
doi:
Substances chimiques
MutL Protein Homolog 1
EC 3.6.1.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
975-984Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Koch-Institut R (2017) Krebs in Deutschland für 2013/2014. Robert Koch-Institut. https://doi.org/10.17886/rkipubl-2017-007
doi: 10.17886/rkipubl-2017-007
Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C, Group E-E-EECCW (2016) ESMO-ESGO-ESTRO Consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer 26(1):2–30. https://doi.org/10.1097/IGC.0000000000000609
doi: 10.1097/IGC.0000000000000609
pubmed: 26645990
Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, La Jeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, Penzone P, Lombardi J, Dunn P, Cohn DE, Copeland L, Eaton L, Fowler J, Lewandowski G, Vaccarello L, Bell J, Reid G, de la Chapelle A (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66(15):7810–7817. https://doi.org/10.1158/0008-5472.CAN-06-1114
doi: 10.1158/0008-5472.CAN-06-1114
pubmed: 16885385
Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, Arnold ST, Thompson BA, Lose FA, Parsons MT, Walters RJ, Pearson SA, Cummings M, Oehler MK, Blomfield PB, Quinn MA, Kirk JA, Stewart CJ, Obermair A, Young JP, Webb PM, Spurdle AB (2014) Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol 32(2):90–100. https://doi.org/10.1200/JCO.2013.51.2129
doi: 10.1200/JCO.2013.51.2129
pubmed: 24323032
Berends MJ, Wu Y, Sijmons RH, van der Sluis T, Ek WB, Ligtenberg MJ, Arts NJ, ten Hoor KA, Kleibeuker JH, de Vries EG, Mourits MJ, Hollema H, Buys CH, Hofstra RM, van der Zee AG (2003) Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 21(23):4364–4370. https://doi.org/10.1200/JCO.2003.04.094
doi: 10.1200/JCO.2003.04.094
pubmed: 14645426
Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR (2007) Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25(33):5158–5164. https://doi.org/10.1200/JCO.2007.10.8597
doi: 10.1200/JCO.2007.10.8597
pubmed: 17925543
Tafe LJ, Riggs ER, Tsongalis GJ (2013) Lynch syndrome presenting as endometrial cancer. Clin Chem 60(1):111–121. https://doi.org/10.1373/clinchem.2013.206888
doi: 10.1373/clinchem.2013.206888
pubmed: 24193118
Egoavil C, Alenda C, Castillejo A, Paya A, Peiro G, Sanchez-Heras AB, Castillejo MI, Rojas E, Barbera VM, Ciguenza S, Lopez JA, Pinero O, Roman MJ, Martinez-Escoriza JC, Guarinos C, Perez-Carbonell L, Aranda FI, Soto JL (2013) Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS ONE 8(11):e79737. https://doi.org/10.1371/journal.pone.0079737
doi: 10.1371/journal.pone.0079737
pubmed: 24244552
pmcid: 3820559
Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomaki P, Mecklin JP, Jarvinen HJ (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214–218. https://doi.org/10.1002/(sici)1097-0215(19990412)81:2%3c214::aid-ijc8%3e3.0.co;2-l
doi: 10.1002/(sici)1097-0215(19990412)81:2<214::aid-ijc8>3.0.co;2-l
pubmed: 10188721
Vasen HF, Offerhaus GJ, den Hartog Jager FC, Menko FH, Nagengast FM, Griffioen G, van Hogezand RB, Heintz AP (1990) The tumour spectrum in hereditary non-polyposis colorectal cancer: a study of 24 kindreds in the Netherlands. Int J Cancer 46(1):31–34. https://doi.org/10.1002/ijc.2910460108
doi: 10.1002/ijc.2910460108
pubmed: 2365499
Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR (2005) Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105(3):569–574. https://doi.org/10.1097/01.AOG.0000154885.44002.ae
doi: 10.1097/01.AOG.0000154885.44002.ae
pubmed: 15738026
Vasen HF, Watson P, Mecklin JP, Jass JR, Green JS, Nomizu T, Muller H, Lynch HT (1994) The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 14(4B):1675–1678
pubmed: 7979205
Koornstra JJ, Mourits MJ, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH (2009) Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 10(4):400–408. https://doi.org/10.1016/S1470-2045(09)70041-5
doi: 10.1016/S1470-2045(09)70041-5
pubmed: 19341971
Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X, Xicola RM, Rodriguez-Moranta F, Paya A, Jover R, Bessa X, Gastrointestinal Oncology Group of the Spanish Gastroenterological A (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293(16):1986–1994. https://doi.org/10.1001/jama.293.16.1986
doi: 10.1001/jama.293.16.1986
pubmed: 15855432
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la Chapelle A (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851–1860. https://doi.org/10.1056/NEJMoa043146
doi: 10.1056/NEJMoa043146
pubmed: 15872200
Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, Kulke MH, Schrag D, Meyerhardt JA, Fuchs CS, Mayer RJ, Ng K, Steyerberg EW, Syngal S (2017) Development and validation of the PREMM5 model for comprehensive risk assessment of Lynch syndrome. J Clin Oncol 35(19):2165–2172. https://doi.org/10.1200/JCO.2016.69.6120
doi: 10.1200/JCO.2016.69.6120
pubmed: 28489507
pmcid: 5493047
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom, Langversion 1.0, 2018, AWMF Registernummer: 032/034-OL, http://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/ (abgerufen am: 12.10.2019).
Wui-Jin K, Nadeem RA-R, Sarah B, Kristin B, Susana MC, Kathleen RC, Hye Sook C, Christina C, David C, Marta Ann C, Shari D, Oliver D, Patricia JE, Christine MF, Peter F, David KG, Suzanne G, Ernest H, Susan H, Warner KH, John RL, Andrea M, David M, Christa N, Larissa N, Amanda Nickles F, Steven WR, Reynolds RK, Todd T, Stefanie U, Emily W, Catheryn MY, Nicole RM, Jillian LS (2018) Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16(2):170–199. https://doi.org/10.6004/jnccn.2018.0006
doi: 10.6004/jnccn.2018.0006
Randall LM, Pothuri B, Swisher EM, Diaz JP, Buchanan A, Witkop CT, Bethan Powell C, Smith EB, Robson ME, Boyd J, Coleman RL, Lu K (2017) Multi-disciplinary summit on genetics services for women with gynecologic cancers: a society of gynecologic oncology white paper. Gynecol Oncol 146(2):217–224. https://doi.org/10.1016/j.ygyno.2017.06.002
doi: 10.1016/j.ygyno.2017.06.002
pubmed: 28596016
Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O’Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31(1):12–39. https://doi.org/10.1136/ijgc-2020-002230
doi: 10.1136/ijgc-2020-002230
pubmed: 33397713
Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broaddus RJ, Ramirez N, Pritchard CC, Hampel H, Chassen AS, Simmons LV, Schmidt AP, Gao F, Brinton LA, Backes F, Landrum LM, Geller MA, DiSilvestro PA, Pearl ML, Lele SB, Powell MA, Zaino RJ, Mutch D (2015) Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for Lynch syndrome screening in endometrial cancers from GOG210: an NRG oncology and gynecologic oncology group study. J Clin Oncol 33(36):4301–4308. https://doi.org/10.1200/JCO.2015.63.9518
doi: 10.1200/JCO.2015.63.9518
pubmed: 26552419
pmcid: 4678181
Kahn RM, Gordhandas S, Maddy BP, Baltich Nelson B, Askin G, Christos PJ, Caputo TA, Chapman-Davis E, Holcomb K, Frey MK (2019) Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? Cancer 125(18):3172–3183. https://doi.org/10.1002/cncr.32203
doi: 10.1002/cncr.32203
pubmed: 31150123
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268. https://doi.org/10.1093/jnci/djh034
doi: 10.1093/jnci/djh034
pubmed: 14970275
Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116(6):1453–1456. https://doi.org/10.1016/s0016-5085(99)70510-x
doi: 10.1016/s0016-5085(99)70510-x
pubmed: 10348829
Nardon E, Glavac D, Benhattar J, Groenen PJ, Hofler G, Hofler H, Jung A, Keller G, Kirchner T, Lessi F, Ligtenberg MJ, Mazzanti CM, Winter G, Stanta G (2010) A multicenter study to validate the reproducibility of MSI testing with a panel of 5 quasimonomorphic mononucleotide repeats. Diagn Mol Pathol 19(4):236–242. https://doi.org/10.1097/PDM.0b013e3181db67af
doi: 10.1097/PDM.0b013e3181db67af
pubmed: 21051996
Bettstetter M, Dechant S, Ruemmele P, Vogel C, Kurz K, Morak M, Keller G, Holinski-Feder E, Hofstaedter F, Dietmaier W (2008) MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed and paraffin-embedded tissue samples. Lab Invest 88(12):1367–1375. https://doi.org/10.1038/labinvest.2008.100
doi: 10.1038/labinvest.2008.100
pubmed: 18936738
Heitz F, Amant F, Fotopoulou C, Battista MJ, Wimberger P, Traut A, Fisseler-Eckhoff A, Harter P, Vandenput I, Sehouli J, Schmidt M, Kimmig R, du Bois R, du Bois A (2014) Synchronous ovarian and endometrial cancer–an international multicenter case-control study. Int J Gynecol Cancer 24(1):54–60. https://doi.org/10.1097/IGC.0000000000000019
doi: 10.1097/IGC.0000000000000019
pubmed: 24300466
Lu KH, Ring KL (2015) One size may not fit all: the debate of universal tumor testing for Lynch syndrome. Gynecol Oncol 137(1):2–3. https://doi.org/10.1016/j.ygyno.2015.03.011
doi: 10.1016/j.ygyno.2015.03.011
pubmed: 25818039
Lin DI, Hecht JL (2016) Targeted screening with combined age- and morphology-based criteria enriches detection of Lynch syndrome in endometrial cancer. Int J Surg Pathol 24(4):297–305. https://doi.org/10.1177/1066896916629782
doi: 10.1177/1066896916629782
pubmed: 26842347
Dillon JL, Gonzalez JL, DeMars L, Bloch KJ, Tafe LJ (2017) Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome. Hum Pathol 70:121–128. https://doi.org/10.1016/j.humpath.2017.10.022
doi: 10.1016/j.humpath.2017.10.022
pubmed: 29107668
Kast K, Dobberschutz C, Sadowski CE, Pistorius S, Wimberger P (2016) Prevalence of Lynch syndrome in unselected patients with endometrial or ovarian cancer. Arch Gynecol Obstet 294(6):1299–1303. https://doi.org/10.1007/s00404-016-4180-0
doi: 10.1007/s00404-016-4180-0
pubmed: 27535758
Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348(10):919–932. https://doi.org/10.1056/NEJMra012242
doi: 10.1056/NEJMra012242
pubmed: 12621137
Mills AM, Liou S, Ford JM, Berek JS, Pai RK, Longacre TA (2014) Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol 38(11):1501–1509. https://doi.org/10.1097/pas.0000000000000321
doi: 10.1097/pas.0000000000000321
pubmed: 25229768
pmcid: 4361228
Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, Lynch P, Burke W, Press N (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296(12):1507–1517. https://doi.org/10.1001/jama.296.12.1507
doi: 10.1001/jama.296.12.1507
pubmed: 17003399
Singh H, Schiesser R, Anand G, Richardson PA, El-Serag HB (2010) Underdiagnosis of Lynch syndrome involves more than family history criteria. Clin Gastroenterol Hepatol 8(6):523–529. https://doi.org/10.1016/j.cgh.2010.03.010
doi: 10.1016/j.cgh.2010.03.010
pubmed: 20303416
pmcid: 2879470
Ring KL, Bruegl AS, Allen BA, Elkin EP, Singh N, Hartman AR, Daniels MS, Broaddus RR (2016) Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. Mod Pathol 29(11):1381–1389. https://doi.org/10.1038/modpathol.2016.135
doi: 10.1038/modpathol.2016.135
pubmed: 27443514
pmcid: 5541389
Rubio I, Ibanez-Feijoo E, Andres L, Aguirre E, Balmana J, Blay P, Llort G, Gonzalez-Santiago S, Maortua H, Tejada MI, Martinez-Bouzas C (2016) Analysis of Lynch syndrome mismatch repair genes in women with endometrial cancer. Oncology 91(3):171–176. https://doi.org/10.1159/000447972
doi: 10.1159/000447972
pubmed: 27398995
Trano G, Wasmuth HH, Sjursen W, Hofsli E, Vatten LJ (2009) Awareness of heredity in colorectal cancer patients is insufficient among clinicians: a Norwegian population-based study. Colorectal Dis 11(5):456–461. https://doi.org/10.1111/j.1463-1318.2009.01830.x
doi: 10.1111/j.1463-1318.2009.01830.x
pubmed: 19508550
Sjursen W, Haukanes BI, Grindedal EM, Aarset H, Stormorken A, Engebretsen LF, Jonsrud C, Bjornevoll I, Andresen PA, Ariansen S, Lavik LA, Gilde B, Bowitz-Lothe IM, Maehle L, Moller P (2010) Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. J Med Genet 47(9):579–585. https://doi.org/10.1136/jmg.2010.077677
doi: 10.1136/jmg.2010.077677
pubmed: 20587412
Shia J (2008) Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 10(4):293–300. https://doi.org/10.2353/jmoldx.2008.080031
doi: 10.2353/jmoldx.2008.080031
pubmed: 18556767
pmcid: 2438196
Bharati R, Jenkins MA, Lindor NM, Le Marchand L, Gallinger S, Haile RW, Newcomb PA, Hopper JL, Win AK (2014) Does risk of endometrial cancer for women without a germline mutation in a DNA mismatch repair gene depend on family history of endometrial cancer or colorectal cancer? Gynecol Oncol 133(2):287–292. https://doi.org/10.1016/j.ygyno.2014.03.011
doi: 10.1016/j.ygyno.2014.03.011
pubmed: 24631449
pmcid: 4016812
Bruegl AS, Ring KL, Daniels M, Fellman BM, Urbauer DL, Broaddus RR (2017) Clinical challenges associated with universal screening for Lynch syndrome-associated endometrial cancer. Cancer Prev Res (Philadelphia, Pa) 10(2):108–115. https://doi.org/10.1158/1940-6207.Capr-16-0219
doi: 10.1158/1940-6207.Capr-16-0219
Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67–73. https://doi.org/10.1038/nature12113
doi: 10.1038/nature12113
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication (2017). Accessed 19 Sept 2020